首页> 美国卫生研究院文献>Scientific Reports >Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery
【2h】

Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery

机译:模块化蛋白连接:作为临床前药物发现试剂平台的新范式

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Significant resource is spent by drug discovery project teams to generate numerous, yet unique target constructs for the multiple platforms used to drive drug discovery programs including: functional assays, biophysical studies, structural biology, and biochemical high throughput screening campaigns. To improve this process, we developed Modular Protein Ligation (MPL), a combinatorial reagent platform utilizing Expressed Protein Ligation to site-specifically label proteins at the C-terminus with a variety of cysteine-lysine dipeptide conjugates. Historically, such proteins have been chemically labeled non-specifically through surface amino acids. To demonstrate the feasibility of this approach, we first applied MPL to proteins of varying size in different target classes using different recombinant protein expression systems, which were then evaluated in several different downstream assays. A key advantage to the implementation of this paradigm is that one construct can generate multiple final products, significantly streamlining the reagent generation for multiple early drug discovery project teams.
机译:药物发现项目团队花费了大量资源来为用于驱动药物发现计划的多个平台生成众多但独特的目标构建体,包括:功能测定,生物物理研究,结构生物学和生化高通量筛选活动。为了改善此过程,我们开发了模块化蛋白质连接(MPL),这是一种组合试剂平台,利用表达的蛋白质连接在C末端使用各种半胱氨酸-赖氨酸二肽结合物对蛋白质进行位点特异性标记。从历史上看,此类蛋白质已通过表面氨基酸进行了非特异性化学标记。为了证明此方法的可行性,我们首先使用不同的重组蛋白表达系统将MPL应用于不同目标类别中大小不同的蛋白,然后在几种不同的下游分析中对其进行评估。实施此范例的主要优势在于,一个构建体可以生成多个最终产品,从而大大简化了多个早期药物发现项目团队的试剂生成过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号